Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative moderately fractionated IMRT with/without fluzoparib in soft tissue sarcoma
ChiCTR2400083580Phase 2Not yet recruiting
- Sponsor
- National Cancer Centre Singapore
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of fluzoparib in soft tissue sarcoma (STS) (2 arms), sponsored by National Cancer Centre Singapore. Primary endpoint: Major wound complications within 4 months post-surgery. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
fluzoparib
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on ChiCTR2400083580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400083580.